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Abstract 
Introduction: Policy decisions about prostate cancer screening require data on the natural 
history of histological cancers and the resulting impact of screening. However, the gold 
standard procedure required to identify true positive histological cancer is a full autopsy 
of the gland which is not possible in screening studies, leading to verification bias. We 
aim to estimate the sensitivity of a prostate cancer screening round (PSA result to 
diagnosis) relative to histological cancer. 
Methods:  We developed a framework combining data on UK screened and non-screened 
prostate cancer populations originating from a single round of population-based PSA 
testing among UK men aged 50-69 years, prostate cancer incidence data, and needle 
biopsy data from the published literature.  
Results: Sensitivity of a screening round was highest at age 65-69 years at 33% (95% CI: 
30%-37%) and 24% (95% CI: 21%-28%) for PSA cut-off levels of 3ng/ml and 4ng/ml, 
respectively. Sensitivity was lowest at age 50-54 at 15% (95%CI: 12%-17%) and 9% 
(95%CI: 8%-11%) for PSA cut-off levels of 3ng/ml and 4ng/ml, respectively. In contrast, 
the clinical detection rate in the absence of mass screening, relative to histological cancer, 
varied between 0.2%-0.7% at age 50-54 and 1.2%-2.7% at age 65-69 from 1995 to 2012. 
Conclusions: The framework enabled the sensitivity of a prostate cancer screening round 
relative to histological cancer diagnosis to be estimated and provides a basis to determine 
the impact and cost-effectiveness of prostate cancer screening.   The approach could be 
adapted to inform the sensitivity of other biomarkers, cancers and screening programmes.   
 
Keywords: Screening; sensitivity;   prostate cancer; evidence synthesis; overdiagnosis; 
overdetection 
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Highlights 
 
• A framework to estimate the sensitivity of prostate cancer screening is proposed 
• Sensitivity was highest at age 65-69 years for two PSA cut-off levels 
• Clinical detection in the absence of mass screening was relatively small 
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1. Introduction 
Prostate cancer represents the highest incidence of all cancers in men in Europe and the 
US (23% of all cancers) and is the third main cause of cancer mortality (9% of all cancer 
deaths).[1] Questions remain about the scale of the contribution of early detection and 
treatment.[2-5]  Many screen-detected cases would never have become clinically 
apparent within the man’s lifetime, as undiagnosed histological cancer increases with age 
from 2% (95%CI: 1-3%) between 20-29 years-of-age to 69% (95%CI: 51-83%) by 90-
99 years-of-age.[6]  
 
Public policy decisions for prostate cancer screening programmes rely on natural history 
models and model-based cost-effectiveness analyses as no conclusive data exist, even 
from the two largest prostate cancer screening trials.[4, 5] Such models simulate the 
progression of prostate cancer in the absence and presence of organised screening 
programmes, requiring data on the sensitivity of such programmes in order to simulate 
the number of cases detected and managed in each PSA testing round relative to a pool of 
undetected histological cancers. These models need to simulate the clinical incidence of 
prostate cancer during and after screening, this requires data on both the sensitivity of 
screening and clinical detection rates relative to histological cancer.  
 
This is challenging as the gold standard procedure required to identify histological cancer 
involves the removal and step section biopsies (full slicing of the prostate gland into thin 
sections) undertaken during a full autopsy of the gland. Application of this ‘gold 
standard’ is not possible in screening studies, leading to verification bias, as only those 
with a PSA level above a chosen cut-point are referred for biopsy (and not all diagnosed 
with cancer will receive surgery). Those below the PSA cut-off or for whom cancer was 
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not detected at biopsy do not undergo any step-section biopsy of the prostate gland.  
Furthermore, needle biopsies cannot be viewed as an alternative gold standard procedure 
as their sensitivity can be as low as 30% relative to histological cancer. [7, 8] New 
approaches to prostate cancer diagnosis include the use of high quality Magnetic 
Resonance Imaging (MRI), which may increase rates of detection, particularly for 
anteriorly situated cancers.  [9] 
 
In this study, we estimate the proportion of histological cancers that were detected after a 
single round of population-based PSA testing (i.e. sensitivity) among UK men, stratified 
by PSA cut-off level; the true prevalence of histological prostate cancer in the UK and the 
clinical detection rate in the absence of organised screening.  
 
2. Methods 
2.1. Data and framework 
Prostate ‘screening programme’ refers to the entire patient pathway from the initial PSA 
test to biopsy and diagnostic tests for those with a PSA level above a specified cut-point 
(e.g.  3 or 4ng/ml). The outcome is prostate cancer detection or no cancer detection. 
 
Box 1. Apparent and true prevalence of disease 
• Apparent prevalence: number of men testing positive by a diagnostic test 
(conditional on the initial PSA being above a specified cut-off level) divided by 
the total number of men screened in the population; 
• True prevalence: actual number of men with histological prostate cancer 
divided by the number of men in the population. 
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Expanding previous methodology,[10]  we used the association between true prevalence 
(TP) (see Box 1), based on a definitive gold standard procedure for the screen population 
(i.e. step-section at autopsy amongst men who died of causes other than prostate cancer), 
and apparent prevalence (AP) of prostate cancer, based on diagnostic testing of 
individuals with raised PSA levels in the screened population (i.e. prostate biopsy (initial 
and repeats), digital rectal examination, free-to-total PSA, magnetic resonance imaging 
(MRI) or computerised tomography (CT) scans),[11] 
 
𝐴𝑃 = 𝑇𝑃 × 𝑠𝑒𝑛𝑠 + (1 − 𝑇𝑃) × (1 − 𝑠𝑝𝑒𝑐) Equation (1) 
 
where sens and spec represent the sensitivity and specificity of the screening programme. 
Equation (1) can be arranged to inform the screening programme sensitivity relative to 
histological prostate cancer, i.e. proportion of all prostate cancers (TP) actually detected 
on screening, as, 
𝑠𝑒𝑛𝑠 =
𝐴𝑃
𝑇𝑃
  
Equation (2) 
 
where the specificity of the ‘screening programme’ is assumed to be 100% following 
diagnostic testing as it is very unlikely that men will be wrongly confirmed as having 
prostate cancer following all diagnostic tests post initial PSA and biopsy testing. Hence, 
this conceptualisation of specificity is different from the specificity of the initial prostate 
biopsy test which is high but not perfect.[7] Furthermore, by focusing on screen attenders, 
we explicitly excluded the screening attendance rate so that it can be added subsequently 
as an independent input. 
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Likewise, cancer detection data in non-screen populations represents the apparent 
prevalence (AP) in Equation (2) but the sens component now refers to the proportion of 
histological cancers detected clinically in areas without formal screening, i.e. sensitivity 
of clinical detection or clinical detection rate. 
 
Bibliographic databases were systematically searched for studies reporting on the 
sensitivity of PSA screening and biopsy testing relative to histological cancer (see online 
appendix).[7, 8, 12] UK cancer registries and national databases were interrogated for 
data on the clinical incidence of cancer. Data on a single round of population-based PSA 
testing among UK men came from the ongoing UK-based Prostate testing for cancer and 
Treatment trial (ProtecT) (personal communication from ProtecT). Table 1 reports the 
identified evidence.  
 
2.2. True prevalence of prostate cancer 
We used 25 autopsy studies from a systematic review [6] to estimate the association 
between histological cancer and age as a continuous variable (odds ratio (OR) of 1.06 per 
year increase in age in predominantly white populations) using a Bayesian logistic meta-
regression (see online appendix). This provided informed prior distributions of the 
parameters of true prevalence of histological cancer in age i, 𝑃0,𝑖. 
 
2.3. UK-specific data on screening prevalence  
We obtained screening prevalence data by age-group and PSA cut-off level (3 and 
4ng/ml) from the diagnostic phase of the ongoing UK-based ProtecT trial examining 
treatment options for screen detected men (Table 1, i=1,...,8).[13] In this trial, men aged 
50 to 69 years old in general practices in and around nine cities in the UK were invited to 
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attend an appointment for a PSA test between 2001 and 2009. Those with a PSA level 
above the 3ng/ml cut-off were recommended to receive a standardised protocol of digital 
rectal examination and transrectal ultrasound-guided needle biopsy.  Men diagnosed with 
clinically localised prostate cancer were invited to participate in the trial of 
treatments.[13]  
 
Using Equation (2), the sensitivity of the single round of the ‘screening programme’, 𝜃𝑖,𝑗, 
was estimated by dividing the screening prevalence at age i and PSA cutoff level j (3 and 
4ng/ml), 𝑝𝑟𝑒𝑣𝑖,𝑗
𝑆𝐶𝑅, by the respective histological prevalence of prostate cancer, 𝑃0,𝑖,   
𝜃𝑖,𝑗 =
𝑝𝑟𝑒𝑣𝑖,𝑗
𝑆𝐶𝑅
𝑃0,𝑖
  for i=1,...,4 j=1,2 
 
The sensitivity of the ‘screening programme’ was further assumed to be a function of the 
proportion of histological cancers at age i with PSA levels above the screening cut-off 
level j (𝑝𝑠𝑎𝑖,𝑗
𝑃𝐶𝑎); biopsy acceptance rate at age i (𝑏𝑢𝑝𝑡𝑖) and the sensitivity of the biopsy 
procedure to detect histological cancer (𝑏𝑠𝑒𝑛𝑠𝑃𝑆𝐴), 
𝜃𝑖,𝑗 = 𝑝𝑠𝑎𝑖,𝑗
𝑃𝐶𝑎 × 𝑏𝑢𝑝𝑡𝑖 × 𝑏𝑠𝑒𝑛𝑠
𝑃𝑆𝐴 for i=1,...,4 j=1,2 
 
The biopsy acceptance rate, 𝑏𝑢𝑝𝑡𝑖 , was informed by the diagnostic phase of the ProtecT 
trial (Table 1, i=20,…,24). An autopsy study [12] provided data on the sensitivity of 12-
core needle biopsy, 𝑏𝑠𝑒𝑛𝑠𝑃𝑆𝐴, relative to histological cancers with PSA values equal or 
above 4ng/ml (Table 1, i=17). The authors reported the sensitivity of needle biopsy to be 
similar for histological cancers with PSA values below and above 4ng/ml (53% and 59%, 
respectively) and we assumed the sensitivity of needle biopsy for cancers above PSA 3 
and 4ng/ml to be the same.  
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The proportion of histological cancers with PSA levels above the 3ng/ml and 4 ng/ml 
cutoff (𝑝𝑠𝑎𝑖,𝑗
𝑃𝐶𝑎) was estimated using data from the ProtecT trial and from the autopsy 
study. [12] The proportion of men screened with PSA levels above cut-off level j 
(𝑝𝑠𝑎𝑖,𝑗
𝐴𝐿𝐿) is a weighted average of the proportion of men with and without histological 
cancer (𝑝𝑠𝑎𝑖,𝑗
𝑃𝐶𝑎 and 𝑝𝑠𝑎𝑖,𝑗
𝑁𝑜𝑃𝐶𝑎, respectively) that have PSA levels above cutoff level j. 
The weights used correspond to the true prevalence of histological cancer, 𝑃0,𝑖,  
𝑝𝑠𝑎𝑖,𝑗
𝐴𝐿𝐿 = 𝑝𝑠𝑎𝑖,𝑗
𝑃𝐶𝑎𝑃0,𝑖 + 𝑝𝑠𝑎𝑖,𝑗
𝑁𝑜𝑃𝐶𝑎(1 − 𝑃0,𝑖) for i=1,...,4 j=1,2 
 
Iguchi et al. 2008 [12] reported the proportion of histological cancers with PSA above 
4ng/ml to be 47% in an autopsy series of men deceased with no known history of prostate 
cancer (Table 1, i=19). The expected proportion of histological cancers with PSA 3-
3.9ng/ml was informed by adjusting data from control arm of the Prostate Cancer 
Prevention Trial (PCPT) using the ProtecT screening round (see online appendix) [14] 
The adjustment was needed because men in the PCPT were not representative of the 
patients in ProtecT as they underwent annual PSA screening during the 7 years of the trial 
before the final biopsy. The adjusted proportion of cancers with PSA above 3ng/ml was 
53% compared to 32% reported in the PCPT study.[14]   
 
2.4. UK-specific data on clinical incidence 
Cancer registry data on the number of incident prostate cancer cases by 5-year age groups 
were obtained for England and Wales for 1995, 2005 and 2012 from the UK Office of 
National Statistics (ONS) (Table 1, i=24,..,59). The year 2005 was chosen to match the 
median year when patients were diagnosed in the screened prevalence data from ProtecT.  
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Using Equation (2), the clinical detection rate in areas lacking an organised population-
based screening programme (sensitivity of clinical diagnosis), 𝜙𝑖,𝑗, at age i and year j 
(j=1995, 2005, 2012), was estimated by dividing the proportion of incident cases in the 
population,  𝑝𝑟𝑒𝑣𝑖,𝑗
𝐶𝐿𝐼, by the respective histological prevalence of prostate cancer, 𝑃0,𝑖,   
𝜙𝑖,𝑗 =
𝑝𝑟𝑒𝑣𝑖,𝑗
𝐶𝐿𝐼
𝑃0,𝑖
  for i=1,...,11 
The incidence rates were estimated using the entire male population alive in each 5-year 
age group i and in year j (i.e. 1995, 2005 and 2012) and were assumed to be constant 
within each age group. These were then converted into proportions, 𝑝𝑟𝑒𝑣𝑖,𝑗
𝐶𝐿𝐼 (see online 
appendix). 
 
2.5. Statistical methods 
A Bayesian framework was used to synthesise all available data using likelihood 
functions (e.g. binomial and Poisson processes) to link the observed data (e.g. prevalence 
of PSA detected prostate cancer from the single round of population-based PSA testing in 
ProtecT) with the unknown parameters (e.g. sensitivity of screening programme), update 
any prior information available, and simultaneously estimate joint posterior distributions 
of the parameters of interest. The online appendix provides details on the different types 
of data and parameters being estimated, as well as a directed acyclic graph of the 
statistical framework. Modelling was carried out using Bayesian Markov Monte Carlo 
(MCMC) methods in WINBUGS v.1.4.3.[15] Model selection was based on the posterior 
corrected mean deviance (Dbar) and the Deviance Information Criterion (DIC).[16, 17]  
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3. Results 
Table 2 reports the evidence synthesis framework results.  The histological prevalence of 
cancer by age was estimated to increase from 3% (95%CI: 2%-3%) at age 30 to 66% 
(95%CI: 61%-71%) by age 100.  The sensitivity of the screening programme and of 
clinical diagnosis (in its absence), relative to histological cancer, also increased with age 
with the latter decreasing in men aged 80 years and over across the 3 time periods studied 
(see Appendix Table A.3). The sensitivity of the screening programme with a PSA cut-
off of 3ng/ml varied between 15% (95%CI: 12%-17%) at age 50-54 and 34% (95%CI: 
30%-37%) at age 65-69 (See Appendix Figure A.5). As expected, adopting a lower PSA 
level for referring patients for needle biopsy resulted in higher sensitivity relative to 
histological cancer. For example, adopting a PSA cut-off level of 3ng/ml, the sensitivity 
of the single round of the ‘screening programme’ at age 55-59 was estimated at 22% 
(95%CI: 19%-25%) compared to 15% (95%CI: 13%-18%) if adopting a 4ng/ml cut-off.  
In contrast, the clinical detection rate in the absence of mass screening, relative to 
histological cancer, varied between 0.2%-0.7% at age 50-54 and 1.2%-2.7% at age 65-69 
from 1995 to 2012 (see Appendix Figure A.4). The overall model fit was good 
(Dres=58.2 compared to 55 data points).   
 
The model estimates were fairly robust to changes in the prior distributions. However, the 
assumption and prior distribution for the precision (variance) of the proportion of 
histological cancers above and below the PSA cut-off had an impact on both the model fit 
and estimates (see online appendix). For example, assuming that the distribution of PSA 
levels in histological cancers is constant across age (i.e. fixed), the model fit was poor 
(Dres=285.3, compared to 55 data points).  
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4. Discussion 
This paper presents a framework to estimate the histological prevalence of prostate cancer 
and the proportion of prostate cancers detected by a single round of a screening 
programme, i.e. sensitivity, when it is not possible to observe this directly. This was 
achieved by simultaneously synthesising data from the diagnostic phase of the UK 
ProtecT trial of treatment for localised prostate cancer, data on the incidence of clinically 
detected disease and prior information on the histological prevalence of prostate cancer in 
the population.  
 
We estimated the sensitivity of the screening programme to vary between 15% (95%CI: 
12%-17%) at age 50-54 and 34% (95%CI: 30%-37%) at age 65-69, using a PSA cut-off 
level of 3ng/ml, and 10% (95%CI: 8%-11%) at age 50-54 and 24% (95%CI: 21%-28%) 
at age 65-69 using a PSA cut-off level of 4ng/ml. This is in contrast with clinical 
detection rates relative to histological cancer of 0.7% (95%CI 0.6%-0.8%) to 2.7% 
(95%CI: 2.4-3.0) for these age groups in 2012. Other studies have reported estimates of 
sensitivity, but none is directly comparable to ours. The PCPT trial reported estimates of 
the sensitivity of screening in a US population to be 32.2% and 20.5% at PSA cut-off 
levels of 3ng/ml and 4ng/ml. This was estimated by performing 6-core biopsies in all 
patients at the end of the 7 year trial and estimating the proportion of detected cases with 
a PSA value above each cut-off level out of all biopsy detected cases  [14]. However, 
other researchers have shown 6-core biopsies to have a sensitivity of 30% relative to 
histological cancer.[7] Hence, the PCPT trial estimates refer to prostate cancer detectable 
with a 6-core biopsy which represents a small proportion of the histological cancer 
population. Gann et al. [18] estimated the sensitivity to be 72% at a cut-off of 4ng/ml, by 
estimating how many clinical cases had their PSA values raised within a year before 
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detection. However, their estimates refer to clinically diagnosed cases (not histological 
cancers) and assume that these would have been present at the time of the PSA test.  
 
Our proposed framework and results will enable the explicit incorporation of model 
inputs, such as the sensitivity of screening programmes and prevalence of cancer into 
prostate cancer modelling studies and cost-effectiveness analyses.[19, 20]. These 
important parameter inputs have either been excluded in previous cost-effectiveness 
analysis due to the lack of data[21, 22] or, if included, were informed by assumptions 
about its value, e.g. PSA sensitivity for local prostate cancer varying from 40% to 
80%.[23] Finally, the use of UK-specific clinical incidence and screening prevalence 
enable the estimation of model parameters specific to this jurisdiction while also fully 
characterising all uncertainties, hence, avoiding ad hoc ‘tweaking’ of parameters to match 
external data.[21, 22]  
 
There are several limitations to the approach used in this paper. First, our results are 
subject to the assumptions made about how the different data sources are associated with 
each other. For example, we assumed the cancers detected in the US-based autopsy study 
[12] to be similar to the pool of histological cancers in the screened UK population. We 
judged these populations to be similar as the autopsy population consisted of men, 
predominantly white, with no known history of prostate cancer where the prostate glands 
were examined using the step-section technique [7] and the detected cancers showed a 
similar distribution by age to UK based autopsies and our previous estimates [6]. 
Moreover, despite being a key parameter, data on PSA values in histological cancers are 
limited, consisting of the single autopsy study with 57 cancers without information on 
their age distribution. Understanding the PSA levels in histological cancers by age is as 
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important as determining the sensitivity of needle biopsy as the former will directly affect 
the screening detection rates (only those with a PSA level above a chosen cut-point are 
referred for biopsy). Hence, we tested several models and assumptions in sensitivity 
analysis concerning the autopsy data and the age of men with histological cancer. Also, 
we did not consider data from the PCPT trial on the distribution of PSA values in the 
biopsy detected cancers to be a valid proxy for histological cancers. As all men in the 
PCPT trial had annual measurement of PSA levels (PSA 4ng/ml cut-point) and digital 
rectal examination, we expect the proportion of cases below the cut-off level to be 
overrepresented. Furthermore, it would have been useful to have data on the sensitivity of 
needle biopsy relative to histological cancer for other PSA cut-off levels than 4ng/ml and 
avoid the assumption that it was the same for PSA cut-off levels of 3 and 4ng/ml.[12] 
Nonetheless, it may not be a strong assumption as there seems to be a weak correlation 
between detection rate and PSA levels as the sensitivity of needle biopsy was reported to 
be similar for histological cancers with PSA values below and above 4ng/ml. [12] 
Finally, whilst this analysis was undertaken using conventional PSA-testing as a cancer 
detection tool to trigger prostate biopsies, it is important to emphasise that if screening for 
prostate cancer were to be adopted in the future, methods will evolve to take into account 
other emerging biomarkers, genetic risk factors and imaging technologies in order to 
reduce unnecessary biopsies and over-diagnosis.[24] Nonetheless, the framework 
presented here can be easily expanded to explore the impact of these emerging screening 
technologies.  
 
In conclusion, this study presents a framework for indirectly estimating important input 
parameters for diseases and cost-effectiveness models, such as sensitivity of a screening 
programme, for which no direct evidence exists. This was undertaken using a Bayesian 
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statistical framework to simultaneously combine all evidence sources and estimate means 
and distributions for the parameters of interest. The proposed method provides a 
transparent and systematic approach to make the best use of the available evidence and 
could be adapted to inform other jurisdictions and types of cancer. This will be of benefit 
to researchers and policy makers evaluating the impact of screening in their populations.  
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Tables 
Table 1. Sources of evidence used.  
Ith Data, region, year  (y/n) 
Number of 
cases (y) 
Sample 
size (n) 
Ref 
1 Screened detected cancer PSA>3ng/ml, age 50-54 1.4% 288 20,761 ProtecT 
2 Screened detected cancer PSA>3ng/ml, age 55-59 2.8% 659 23,943 ProtecT 
3 Screened detected cancer PSA>3ng/ml, age 60-64 5.0% 978 19,558 ProtecT 
4 Screened detected cancer PSA>3ng/ml, age 65-69 7.1% 1,065 14,899 ProtecT 
5 Screened detected cancer PSA>4ng/ml, age 50-54 0.9% 178 20,761 ProtecT 
6 Screened detected cancer PSA>4ng/ml, age 55-59 1.8% 435 23,943 ProtecT 
7 Screened detected cancer PSA>4ng/ml, age 60-64 3.5% 687 19,558 ProtecT 
8 Screened detected cancer PSA>4ng/ml, age 65-69 5.2% 779 14,899 ProtecT 
9 Men with PSA>3ng/ml, age 50-54 4.3% 886 20,761 ProtecT 
10 Men with PSA>3ng/ml, age 55-59 8.2% 1,955 23,943 ProtecT 
11 Men with PSA>3ng/ml, age 60-64 14.1% 2,763 19,558 ProtecT 
12 Men with PSA>3ng/ml, age 65-69 19.7% 2,936 14,899 ProtecT 
13 Men with PSA>4ng/ml, age 50-54 2.1% 437 20,761 ProtecT 
14 Men with PSA>4ng/ml, age 55-59 4.5% 1,085 23,943 ProtecT 
15 Men with PSA>4ng/ml, age 60-64 8.3% 1,620 19,558 ProtecT 
16 Men with PSA>4ng/ml, age 65-69 12.4% 1,842 14,899 ProtecT 
17 
Sensitivity of biopsy relative to histological 
cancer with PSA>4ng/ml, 12 core (MPZ+LPZ) 
59.3% 16 27 Iguchi 2008 
18 Histological cancers with PSA>3ng/ml  53.4% 30 57 Iguchi 2008 
19 Histological cancers with PSA>4ng/ml 47.4% 27 57 Iguchi 2008 
20 Men with biopsy out of PSA>3ng/ml, age 50-54 90.2% 799 886 ProtecT 
21 Men with biopsy out of PSA>3ng/ml, age 55-59 90.3% 1,765 1,955 ProtecT 
22 Men with biopsy out of PSA>3ng/ml, age 60-64 88.5% 2,444 2,763 ProtecT 
23 Men with biopsy out of PSA>3ng/ml, age 65-69 86.6% 2,544 2,936 ProtecT 
24 Incidence of prostate cancer, age 30-34, 1995 0.00% 0 2,027,900 ONS 
25 Incidence of prostate cancer, age 35-39, 1995 0.00% 1 1,781,900 ONS  
26 Incidence of prostate cancer, age 40-44, 1995 0.00% 10 1,650,800 ONS  
27 Incidence of prostate cancer, age 45-49, 1995 0.00% 60 1,808,500 ONS  
28 Incidence of prostate cancer, age 50-54, 1995 0.01% 213 1,471,100 ONS  
29 Incidence of prostate cancer, age 55-59, 1995 0.05% 698 1,324,300 ONS  
30 Incidence of prostate cancer, age 60-64, 1995 0.13% 1,551 1,206,700 ONS  
31 Incidence of prostate cancer, age 65-69, 1995 0.25% 2,805 1,107,100 ONS  
32 Incidence of prostate cancer, age 70-74, 1995 0.42% 4,052 971,300 ONS  
33 Incidence of prostate cancer, age 75-79, 1995 0.62% 3,840 623,000 ONS  
34 Incidence of prostate cancer, age 80-84, 1995 0.85% 3,448 407,900 ONS  
35 Incidence of prostate cancer, age 85+, 1995 1.09% 2,549 233,100 ONS  
36 Incidence of prostate cancer, age 30-34, 2005 0.00% 0 1,855,700 ONS 
37 Incidence of prostate cancer, age 35-39, 2005 0.00% 8 2,055,300 ONS  
38 Incidence of prostate cancer, age 40-44, 2005 0.00% 35 2,017,500 ONS  
39 Incidence of prostate cancer, age 45-49, 2005 0.01% 193 1,765,100 ONS  
40 Incidence of prostate cancer, age 50-54, 2005 0.04% 700 1,601,200 ONS  
41 Incidence of prostate cancer, age 55-59, 2005 0.15% 2,505 1,714,100 ONS  
 42 Incidence of prostate cancer, age 60-64, 2005 0.29% 3,937 1,350,500 ONS  
43 Incidence of prostate cancer, age 65-69, 2005 0.50% 5,827 1,154,300 ONS  
44 Incidence of prostate cancer, age 70-74, 2005 0.63% 6,024 958,500 ONS  
45 Incidence of prostate cancer, age 75-79, 2005 0.73% 5,458 748,400 ONS  
46 Incidence of prostate cancer, age 80-84, 2005 0.77% 3,889 507,300 ONS  
47 Incidence of prostate cancer, age 85+, 2005 0.81% 2,556 317,000 ONS  
48 Incidence of prostate cancer, age 30-34, 2012 0.00% 0 1,798,016 ONS 
49 Incidence of prostate cancer, age 35-39, 2012 0.00% 9 1,707,213 ONS  
50 Incidence of prostate cancer, age 40-44, 2012 0.00% 70 1,901,368 ONS  
51 Incidence of prostate cancer, age 45-49, 2012 0.02% 330 1,939,398 ONS  
52 Incidence of prostate cancer, age 50-54, 2012 0.06% 1,105 1,748,433 ONS  
53 Incidence of prostate cancer, age 55-59, 2012 0.17% 2,618 1,509,855 ONS  
 20 
 
54 Incidence of prostate cancer, age 60-64, 2012 0.34% 4,961 1,476,180 ONS  
55 Incidence of prostate cancer, age 65-69, 2012 0.57% 7,779 1,358,608 ONS  
56 Incidence of prostate cancer, age 70-74, 2012 0.69% 6,723 972,550 ONS  
57 Incidence of prostate cancer, age 75-79, 2012 0.80% 6,249 777,026 ONS  
58 Incidence of prostate cancer, age 80-84, 2012 0.74% 3,983 538,259 ONS  
59 Incidence of prostate cancer, age 85+, 2012 0.81% 3,307 406,695 ONS  
      
MPZ: Mid peripheral zone, LPZ: lateral peripheral zone. 
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Table 2. Estimated parameters (mean and 95%CI) 
Parameters Mean  Low 
95%CI 
High 
95%CI 
Sensitivity of biopsy relative to histological cancer  (%) 48 45 50 
Sensitivity of screening round with PSA>3ng/ml at age 50-54 (%)  15 12 17 
Sensitivity of screening round with PSA>3ng/ml at age 55-59 (%) 22 19 26 
Sensitivity of screening round with PSA>3ng/ml at age 60-64 (%) 31 27 34 
Sensitivity of screening round with PSA>3ng/ml at age 65-69 (%) 34 30 37 
Sensitivity of screening round with PSA>4ng/ml at age 50-54 (%)  10 8 11 
Sensitivity of screening round with PSA>4ng/ml at age 55-59 (%) 15 13 18 
Sensitivity of screening round with PSA>4ng/ml at age 60-64 (%) 21 18 25 
Sensitivity of screening round with PSA>4ng/ml at age 65-69 (%) 24 21 28 
Clinical detection rate at age 50-54 (%), 1995 0.2 0.1 0.2 
Clinical detection rate at age 55-59 (%), 1995 0.4 0.4 0.5 
Clinical detection rate at age 60-64 (%), 1995 0.8 0.7 0.9 
Clinical detection rate at age 65-69 (%), 1995 1.2 1.1 1.4 
Clinical detection rate at age 50-54 (%), 2005 0.5 0.4 0.5 
Clinical detection rate at age 55-59 (%), 2005 1.2 1.0 1.3 
Clinical detection rate at age 60-64 (%), 2005 1.8 1.6 2.0 
Clinical detection rate at age 65-69 (%), 2005 2.4 2.1 2.7 
Clinical detection rate at age 50-54 (%), 2012 0.7 0.6 0.8 
Clinical detection rate at age 55-59 (%), 2012 1.4 1.2 1.6 
Clinical detection rate at age 60-64 (%), 2012 2.1 1.8 2.3 
Clinical detection rate at age 65-69 (%), 2012 2.7 2.4 3.0 
Histological cancer at age 30 (%) 3 2 3 
Histological cancer at age 40 (%) 5 4 6 
Histological cancer at age 50 (%) 8 7 10 
Histological cancer at age 60 (%) 14 12 16 
Histological cancer at age 70 (%) 23 21 26 
Histological cancer at age 80 (%) 36 32 40 
Histological cancer at age 90 (%) 51 46 56 
Histological cancer at age 100 (%) 66 60 71 
Proportion of histological cancers with PSA>3ng/ml (50-54) (%) 34 28 40 
Proportion of histological cancer with PSA>3ng/ml (55-59) (%) 52 44 59 
Proportion of histological cancer with PSA>3ng/ml (60-64) (%) 73 64 81 
Proportion of histological cancer with PSA>3ng/ml (65-69) (%) 81 73 88 
Proportion of men without cancer with PSA>3ng/ml (50-54) (%) 1.2 0.7 1.7 
Proportion of men without cancer with PSA>3ng/ml (55-59) (%) 1.9 1.2 2.7 
Proportion of men without cancer with PSA>3ng/ml (60-64) (%) 2.6 1.4 3.9 
Proportion of men without cancer with PSA>3ng/ml (65-69) (%) 3.2 1.4 4.9 
Proportion of histological cancers with PSA>4ng/ml (50-54) (%) 22 18 26 
Proportion of histological cancer with PSA>4ng/ml (55-59) (%) 35 30 40 
Proportion of histological cancer with PSA>4ng/ml (60-64) (%) 51 45 57 
Proportion of histological cancer with PSA>4ng/ml (65-69) (%) 59 52 66 
Proportion of men without cancer with PSA>4ng/ml (50-54) (%) 0.0 0.0 0.0 
Proportion of men without cancer with PSA>4ng/ml (55-59) (%) 0.0 0.0 0.0 
Proportion of men without cancer with PSA>4ng/ml (60-64) (%) 0.0 0.0 0.0 
Proportion of men without cancer with PSA>4ng/ml (65-69) (%) 0.0 0.0 0.0 
pD 51.5   
Dres 58.2   
DIC 109.7   
pD: effective number of parameters; DIC: deviance information criterion; Dres: sum of individual deviance 
residual contributions of data points. 
 
